Austin Christopher, Alassas Khadija, Burger Charles, Safford Robert, Pagan Ricardo, Duello Katherine, Kumar Preetham, Zeiger Tonya, Shapiro Brian
Division of Cardiovascular Disease, Mayo Clinic, Mayo Foundation for Medical Education and Research, Jacksonville, FL.
Division of Pulmonary Disease, Mayo Clinic, Mayo Foundation for Medical Education and Research, Jacksonville, FL.
Chest. 2015 Jan;147(1):198-208. doi: 10.1378/chest.13-3035.
Elevated mean right atrial pressure (RAP) measured by cardiac catheterization is an independent risk factor for mortality. Prior studies have demonstrated a modest correlation with invasive and noninvasive echocardiographic RAP, but the prognostic impact of estimated right atrial pressure (eRAP) has not been previously evaluated in patients with pulmonary arterial hypertension (PAH).
A retrospective analysis of 121 consecutive patients with PAH based on right-sided heart catheterization and echocardiography was performed. The eRAP was calculated by inferior vena cava diameter and collapse using 2005 and 2010 American Society of Echocardiography (ASE) definitions. Accuracy and correlation of eRAP to RAP was assessed. Kaplan-Meier survival analysis by eRAP, right atrial area, and Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry) risk criteria as well as univariate and multivariate analysis of echocardiographic findings was performed.
Elevation of eRAP was associated with decreased survival time compared with lower eRAP (P < .001, relative risk = 7.94 for eRAP > 15 mm Hg vs eRAP ≤ 5 mm Hg). Univariate analysis of echocardiographic parameters including eRAP > 15 mm Hg, right atrial area > 18 cm², presence of pericardial effusion, right ventricular fractional area change < 35%, and at least moderate tricuspid regurgitation was predictive of poor survival. However, multivariate analysis revealed that eRAP > 15 mm Hg was the only echocardiographic risk factor that was predictive of mortality (hazard ratio = 2.28, P = .037).
Elevation of eRAP by echocardiography at baseline assessment was strongly associated with increased risk of death or transplant in patients with PAH. This measurement may represent an important prognostic component in the comprehensive echocardiographic evaluation of PAH.
通过心导管检查测得的平均右心房压力(RAP)升高是死亡率的独立危险因素。先前的研究已证明其与有创和无创超声心动图测量的RAP存在适度相关性,但肺动脉高压(PAH)患者中估计右心房压力(eRAP)的预后影响此前尚未得到评估。
基于右侧心导管检查和超声心动图对121例连续的PAH患者进行回顾性分析。使用2005年和2010年美国超声心动图学会(ASE)的定义,通过下腔静脉直径和塌陷情况计算eRAP。评估eRAP与RAP的准确性和相关性。采用eRAP、右心房面积以及评估PAH疾病早期和长期管理注册研究(REVEAL注册研究)风险标准进行Kaplan-Meier生存分析,并对超声心动图检查结果进行单因素和多因素分析。
与较低的eRAP相比,eRAP升高与生存时间缩短相关(P <.001,eRAP > 15 mmHg与eRAP≤5 mmHg相比,相对风险 = 7.94)。对包括eRAP > 15 mmHg、右心房面积 > 18 cm²、心包积液的存在、右心室面积变化分数 < 35%以及至少中度三尖瓣反流在内的超声心动图参数进行单因素分析,可预测生存不良。然而,多因素分析显示eRAP > 15 mmHg是唯一可预测死亡率的超声心动图危险因素(风险比 = 2.28,P =.037)。
在基线评估时通过超声心动图测得的eRAP升高与PAH患者死亡或移植风险增加密切相关。该测量可能是PAH综合超声心动图评估中的一个重要预后指标。